SOAT1 and Miyoshi myopathy: The pan-JAK2 inhibitor ruxolitinib, by reducing levels of phosphorylation of STAT-Ser-727 in neutrophils that have only a few mitochondria, can globally reduce autophagy induction and potentially revert the pro-inflammatory contribution of neutrophils to MM survival.